8 August 2022 | By Ria Kakkad (Drug Target Review)
The vaccine attaches spike proteins from SARS-CoV-2 and seven other SARS-like betacoronaviruses to a protein nanoparticle structure, to induce the production of a broad spectrum of cross-reactive antibodies.